Alzamend Neuro Files Proxy Statement Amendment

TL;DR

Alzamend Neuro filed a proxy amendment on 6/11/24, no fee required.

AI Summary

Alzamend Neuro, Inc. filed an amendment (DEFA14A) on June 11, 2024, regarding its proxy statement. The filing indicates no fee was required for this submission, which is classified as Definitive Additional Materials. The company is involved in the pharmaceutical preparations industry and is incorporated in Delaware.

Why It Matters

This filing provides updated information to shareholders regarding company matters, which is crucial for their voting decisions at shareholder meetings.

Risk Assessment

Risk Level: low — This filing is a routine amendment to a proxy statement and does not contain new financial information or strategic changes that would inherently increase risk.

Key Players & Entities

• Alzamend Neuro, Inc. (company) — Registrant
• 0001214659-24-010822 (filing_id) — Accession Number
• 20240611 (date) — Filing Date
• 3500 LENOX RD. NE SUITE 1500 ATLANTA GA 30326 (address) — Business Address

FAQ

Filing Documents

• e611243defa14a.htm (DEFA14A) — 15KB
• alzamendlogo_sm.jpg (GRAPHIC) — 18KB
• 0001214659-24-010822.txt ( ) — 41KB

From the Filing

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, For Use of the Commission Only (as Permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy Statement x Definitive Additional Materials ¨ Soliciting Material Pursuant to § 240.14a-12 ALZAMEND NEURO, INC. (Name of Registrant as Specified in its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box): x No fee required ¨ Fee computed on table below per Exchange Act Rules 14a-6(i) (1) and 0-11. (1) Title of each class of securities to which transaction applies: (2) Aggregate number of securities to which transaction applies: (3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined): (4) Proposed maximum aggregate value of transaction: (5) Total fee paid: ¨ Fee paid previously with preliminary materials: ¨ Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing. (1) Amount Previously Paid: (2) Form, Schedule or Registration Statement No.: (3) Filing Party: (4) Date Filed: ALZAMEND NEURO, INC. 3480 Peachtree Road NE, Second Floor, Suite 103 Atlanta, GA 30326 SUPPLEMENT TO PROXY STATEMENT FOR 2024 SPECIAL MEETING OF STOCKHOLDERS The following information supplements and amends the Definitive Proxy Statement (the “ Proxy Statement ”) of Alzamend Neuro, Inc. (the “ Company ”) that the Company filed with the Securities and Exchange Commission (the “ SEC ”) on May 31, 2024 in connection with the solicitation of proxies by the Company’s Board of Directors (the “ Board ”) for the Company’s Special Meeting of Stockholders (the “ Meeting ”) to be held in a virtual meeting format only on Monday, July 8, 2024, at 12:00 PM Eastern Time. This corrects and supplements statements concerning the number of shares of Capital Stock that are entitled to vote and the number required to constitute a quorum under the heading “ Who is Entitled to Vote; Vote Required; Quorum ” on page 2 of the Proxy Statement. This supplement to the Proxy Statement (this “ Supplement ”) is furnished in connection with the solicitation of proxies by the Board for use at the Meeting. Capitalized terms used in this Supplement and not otherwise defined have the meaning given to such terms in the Proxy Statement. In calculating the number of votes entitled to be cast at the Meeting, the Company inadvertently calculated 1,719,537 as the number of votes entitled to be cast by the holders of Shares A Preferred Stock, instead of 1,375,310 votes. The former number reflected the number of shares of Common Stock that the outstanding Series A Preferred Stock were convertible into, without regard to the NYSE American rules and regulations, as of the Record Date. The latter number reflects the maximum number of votes that the Series A Preferred Stock is entitled to be cast until such time as Proposal No. 1 has been approved by the Company’s stockholders. The 1,375,310 figured, and the NYSE American limitation, were already disclosed in the second and third paragraphs under the heading. As a result, under the heading “ Who is Entitled to Vote; Vote Required; Quorum ” on page 2, the third and fourth paragraphs under this heading are hereby amended and restated in their entirety to read as follows: A majority of the total votes entitled to be cast will constitute a quorum at the Meeting; of the 11,157,921 outstanding shares of Capital Stock, or 5,578,961 such shares, will constitute a quorum at the Meeting, provided that no more than 1,375,310 shares of Series A Preferred Stock and Common Stock held by the Investor that may be voted will be counted as part of the Capital Stock, as only a portion of the Common Stock and Series A Preferred Stock held by the Investor will be eligible to vote on the matters to be presented to the stockholders. Accordingly, for purposes of the votes eligible to be cast at the Meeting, the term “ Eligible Capital Stock ” as used herein shall mean 9,782,611 such shares for purposes of Proposal No. 1 and 11,157,921 such shares for purposes of Proposal No. 2. Except as set forth in this Supplement, all information set forth in the Proxy Statement remains unchanged. Pl

View Full Filing

View this DEFA14A filing on SEC EDGAR